← Back to Search

TMS Brain Signal Measurement in Healthy Subjects

N/A
Recruiting
Led By David J Levinthal, MD PhD
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up multiple study sessions spanning up to 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial studies how to non-invasively measure brain signals in the stomach using magnetic stimulation and brain signals.

Who is the study for?
This trial is for healthy individuals interested in participating in a study to understand how the brain can influence stomach functions. Specific eligibility criteria are not provided, but typically participants should be free from any medical conditions that could interfere with the study.
What is being tested?
The study is testing a non-invasive brain stimulation technique called Transcranial Magnetic Stimulation (TMS) to see how it affects signals going to the stomach. The goal is to find out the best settings and areas of the brain to use for this method.
What are the potential side effects?
TMS may cause mild headaches or scalp discomfort at the site of stimulation, lightheadedness, or tingling sensations. It's generally considered safe with no serious side effects when performed correctly.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~multiple study sessions spanning up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and multiple study sessions spanning up to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in GEP hotspot location
Change in optimal stimulation parameters at GEP hotspot
Secondary study objectives
Effect of neuromodulation
Effect of satiety

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: All participantsExperimental Treatment1 Intervention
All participants

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,792 Previous Clinical Trials
16,359,831 Total Patients Enrolled
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,385 Previous Clinical Trials
652,533 Total Patients Enrolled
David J Levinthal, MD PhDPrincipal InvestigatorUniversity of Pittsburgh
1 Previous Clinical Trials
110 Total Patients Enrolled

Media Library

All participants Clinical Trial Eligibility Overview. Trial Name: NCT05924009 — N/A
Healthy Subjects Research Study Groups: All participants
Healthy Subjects Clinical Trial 2023: All participants Highlights & Side Effects. Trial Name: NCT05924009 — N/A
All participants 2023 Treatment Timeline for Medical Study. Trial Name: NCT05924009 — N/A
~80 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top